The clinical impact of different assays for prostate specific antigen

Semjonow, Axel; Angelis, G. De; Oberpenning, F.; Schmid, Hans‐Peter; Brandt, Burkhard; Hertle, L.

doi:10.1046/j.1464-410x.2000.00858.x

Cited by 43 publications

(24 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As was expected (3,13), assay suppliers who developed assays for free PSA, but whose total PSA assays were not equimolarresponse assays, made efforts to modify their total PSA assays. Consequently, nonequimolar-response assays have already been superseded or withdrawn (14) and it can be anticipated that more assay modifications will appear on the market (10).…”

Section: Discussionmentioning

confidence: 99%

“…A reduction in interassay variability may be accomplished (18) when calibrators made available recently (19) are applied to equimolar-response assays. Until PSA assay standardization is achieved, establishment of assay-specific reference ranges is strongly recommended to avoid misinterpretation of PSA concentrations (10,13,20,21).…”

Section: Discussionmentioning

confidence: 99%

“…The modification of the ACS assay (ACS PSA2, Chiron) did not demonstrate equimolar-response assay characteristics and the AUC remained unchanged as compared with the original test (6). However, the modification of the ACS assay (ACS PSA2, Chiron) reported lower total PSA concentrations on testing identical samples (10).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A New Modification of the Chiron ACS Assay for Total Prostate-Specific Antigen Achieves Equimolar Response Characteristics and Improves the Detection of Prostate Cancer

Oberpenning¹,

Weining²,

Brandt³

et al. 2003

Clinical Chemistry and Laboratory Medicine

View full text Add to dashboard Cite

Nonequimolar-response assays for prostate-specific antigen (PSA) are criticized for overestimating total PSA in some men without prostate cancer (PCA), and underestimating total PSA in some men with PCA. We recently studied three nonequimolar-response PSA assays that had undergone modifications. While two of the studied assays achieved equimolar-response characteristics with improved areas under receiver operating characteristic (ROC) curves (AUC), the modification of the Chiron ACS PSA assay (ACS PSA2, Chiron) failed to achieve this. Recently, the ACS assay underwent another modification (ACS PSA, Bayer), which we investigated.Sera from 305 men (155 without and 150 with PCA, PSA ≥ 2 and ≤ 30 µg/l, Tandem-E) were measured using both modifications of the ACS assay and equimolar-response reference methods (Tandem-R free and Tan

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A New Modification of the Chiron ACS Assay for Total Prostate-Specific Antigen Achieves Equimolar Response Characteristics and Improves the Detection of Prostate Cancer

Oberpenning¹,

Weining²,

Brandt³

et al. 2003

Clinical Chemistry and Laboratory Medicine

View full text Add to dashboard Cite

show abstract

“…Prostate cancer is an important growing health problem, presenting a challenge to urologists, radiologists and pathologist 1,2 Currently, many men are identified as having early prostate cancer through the use of prostate specific antigen (PSA) screening 3,4,5,6 . Carcinoma of the prostate is the most common malignant tumor in men over the age of 65 years 7 , with an estimated 41,000 Americans dying from prostate cancer annually 8 .…”

Section: Introductionmentioning

confidence: 99%

Diagnostic Utility of Prostate Specific Antigen for Detection of Prostatic Lesions

Jasani¹,

Patel²,

Gheewala³

et al. 2012

Int J of Biomed & Adv Res

View full text Add to dashboard Cite

show abstract

“…(1 )]. These assay-dependent variations could lead to misinterpretation of individual PSA values and erroneous clinical decisions about prostate carcinoma (PCa).…”

mentioning

confidence: 99%

Interchangeability of Measurements of Total and Free Prostate-Specific Antigen in Serum with 5 Frequently Used Assay Combinations: An Update

et al. 2006

View full text Add to dashboard Cite

Background:The comparability of total and free prostate-specific antigen (tPSA and fPSA) results among commercial PSA assays has been suggested to be improved by calibration to WHO PSA reference materials and the development of equimolar-response assays. To characterize the current situation, we assessed 5 frequently used commercial assay combinations for tPSA and fPSA regarding the interchangeability of the PSA values and the ratio of fPSA to tPSA (%fPSA), equimolar characteristics, and diagnostic accuracy.

show abstract

The clinical impact of different assays for prostate specific antigen

Cited by 43 publications

References 39 publications

A New Modification of the Chiron ACS Assay for Total Prostate-Specific Antigen Achieves Equimolar Response Characteristics and Improves the Detection of Prostate Cancer

A New Modification of the Chiron ACS Assay for Total Prostate-Specific Antigen Achieves Equimolar Response Characteristics and Improves the Detection of Prostate Cancer

Diagnostic Utility of Prostate Specific Antigen for Detection of Prostatic Lesions

Interchangeability of Measurements of Total and Free Prostate-Specific Antigen in Serum with 5 Frequently Used Assay Combinations: An Update

Contact Info

Product

Resources

About